Showing results (231-240 of 425) with videos related to
Sort By:
Pageof 43
Cancer|August 30, 2008
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, et al.Expert Review of Vaccines|February 22, 2011
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccinesLinda C Benavides, Alan K Sears, Jeremy D Gates, et al.Breast Cancer Research : BCR|May 25, 2012
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomyLaura S Dominici, Elizabeth A Mittendorf, Xumei Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancerAbigail S Caudle, Ana M Gonzalez-Angulo, Kelly K Hunt, et al.Annals of Surgery|September 10, 2014
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical TrialJudy C Boughey, Linda M McCall, Karla V Ballman, et al.Journal of Clinical Medicine|October 16, 2025
Preliminary Efficacy/Feasibility Study of a Breast Cancer-Related Lymphedema Prospective Screening and Early Intervention Program at the Dana-Farber Brigham Cancer CenterSara P Myers, Jacob M Jasper, Tessa Higgins, et al.Biorxiv : the Preprint Server for Biology|November 14, 2023
Quality Control for Single Cell Analysis of High-plex Tissue Profiles using CyLinterGregory J Baker, Edward Novikov, Ziyuan Zhao, et al.Nature Methods|October 31, 2024
Quality control for single-cell analysis of high-plex tissue profiles using CyLinterGregory J Baker, Edward Novikov, Ziyuan Zhao, et al.Oncotarget|March 19, 2024
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancerHaven R Garber, Sreyashi Basu, Sonali Jindal, et al.Annals of Surgical Oncology|May 8, 2026
Receipt of Combined Axillary Dissection and Nodal Irradiation Varies by AgeSara P Myers, Yevgeniya Gokun, Brandon Slover, et al.Pageof 43